Marcin Płonowski

Outcome of acute lymphoblastic leukemia in children with down syndrome—Polish pediatric leukemia and lymphoma study group report

ABSTRACT Children with Down syndrome (DS) have a 20-fold increased risk of developing leukemia compared with the general population. The aim of the study was to analyze the outcome of patients diagnosed with Down syndrome and acute lymphoblastic leukemia (ALL) in Poland between the years 2003 and 2010. A total of 1848 children were diagnosed with ALL (810 females and 1038 males). Of those, 41 (2.2%) had DS. The children were classified into three risk groups: a standard-risk group—14 patients, an intermediate-risk group—24, a high-risk group—3. All patients were treated according to ALLIC 2002 protocol. The median observation time of all patients was 6.1 years, and in patients with DS 5.3 years. Five-year overall survival (OS) was the same in all patients (86% vs 86%, long-rank test, p = .9). The relapse-free survival (RFS) was calculated as 73% in patients with DS and 81% in patients without DS during a median observation time (long-rank test, p = .3). No statistically significant differences were found in the incidence of nonrelapse mortality between those two groups of patients (p = .72). The study was based on children with ALL and Down syndrome who were treated with an identical therapy schedule as ALL patients without DS, according to risk group. This fact can increase the value of the presented results.

Improvement of cure after hematopoietic stem cel transplantations in children

Wstep. Transplantacja komorek krwiotworczych (HSCT) jest wazną metodą terapeutyczną w wielu wrodzonych i nabytych chorobach, w tym nowotworowych, zespolach niewydolności szpiku oraz zaburzeniach immunologicznych i metabolicznych. Celem pracy jest analiza wynikow HSCT w pojedynczym ośrodku pediatrycznym w okresie 12 lat. Pacjenci i metodyka. Analizie poddano wyniki przeszczepien wykonanych w latach 2003-2015 w Klinice Pediatrii, Hematologii i Onkologii w Bydgoszczy. Transplantacje analizowano w trzech przedzialach czasowych: 2004-2007, 2008-2011 oraz 2012-2015. Wyniki. Wykonano 318 HSCT, w tym 186 alloge-nicznych (68 zgodnych rodzinnych i 118 od dawcow alternatywnych) oraz 132 autologiczne. Średnie przezycie po HSCT, wyznaczone metodą Kaplana-Meiera wynioslo 8,1 lat. Calkowite prawdopodobienstwo przezycia (pOS) wynioslo 0,64±0,03; pOS po allo-HSCT wynosi 0,62±0,04, a po auto-HSCT 0,67±0,05. Nie wykazano znamiennych roznic w pOS zarowno po allo-HSCT, jak i po auto-HSCT pomiedzy drugim (2008-2011) i trzecim (2012-2015) analizowanym okresie. Jednakze, pOS bylo wyzsze w dru-gim i trzecim okresie w stosunku do okresu pierwszego (2004-2007), zarowno dla wszystkich pacjentow, jak i u pacjentow po auto-HSCT. W grupie pacjentow allo-HSCT, uzyskano wzrost pOS o ponad 20% (43% vs 66% vs 64% w kolejnych przedzialach czasu; ns). Wnioski. Wyniki HSCT uzyskiwane aktualnie w na-szym ośrodku są porownywalne z wynikami podawanymi w miedzynarodowych rejestrach.

Clinical characteristics and analysis of treatment result in children with Ph-positive acute lymphoblastic leukaemia in Poland between 2005 and 2017

The aim of this study was to analyse the clinical characteristics and outcome of children diagnosed with Ph+ ALL.